Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q8N205

UPID:
SYNE4_HUMAN

ALTERNATIVE NAMES:
KASH domain-containing protein 4; Nuclear envelope spectrin repeat protein 4

ALTERNATIVE UPACC:
Q8N205; A8MRS0; A8MYE3; Q7Z7L3

BACKGROUND:
The protein Nesprin-4 is integral to the LINC complex, ensuring the nuclear envelope's connection with the cytoskeleton. Its function as a kinesin cargo is pivotal for the proper positioning of the nucleus and the cellular architecture, particularly in secretory epithelial cells. This is achieved through the kinesin-dependent positioning of cellular organelles.

THERAPEUTIC SIGNIFICANCE:
Given Nesprin-4's critical role in the onset of progressive high-frequency hearing impairment associated with Deafness, autosomal recessive, 76, targeting this protein could offer a novel approach to managing this condition. The exploration of Nesprin-4's functions and interactions opens new avenues for the development of targeted therapies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.